Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), announced results from an ongoing phase IIb study of IDX184 in combination with pegylated interferon ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE